ISIN Update-DBV Technologies-Viaskin Treatment
ISIN.net Update: DBV Technologies Follow-Up Study of Viaskin® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children Findings support Viaskin® Peanut’s efficacy, compliance and safety profile After 24 months, 80% of treated children respond to Viaskin Peanut 250 microg 12-month response rate in treatment-naïve patients consistent with previously-reported results On…